Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Fremanezumab in Children and Adolescents with Migraine - PubMed

3 hours ago

Fremanezumab is the first monoclonal antibody targeting the CGRP pathway approved for pediatric migraine prevention in patients aged 6-17 years.
The pivotal phase three SPACE trial demonstrated significant reductions in monthly migraine and headache days, with nearly half of participants achieving a ≥50% response rate.
Fremanezumab follows a two-compartment model with a terminal half-life of approximately 30 days in pediatric patients, similar to adults, with body weight as the primary determinant of exposure.
The US FDA approved fremanezumab in August 2025 based on efficacy and safety data consistent with adult studies.
Unresolved issues include potential long-term effects of CGRP blockade on vascular regulation, bone metabolism, and neurodevelopment during growth.
Traditional preventive treatments for pediatric migraine have limited efficacy and tolerability data, making fremanezumab a novel and mechanism-based option.

Hasty Briefsbeta